{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T08:44:58Z","timestamp":1782809098200,"version":"3.54.5"},"reference-count":26,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"1","content-domain":{"domain":["spj.science.org"],"crossmark-restriction":true},"short-container-title":["Comput Struct Biotechnol J"],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Many diseases evolve through complex, nonlinear trajectories shaped by interacting genetic, cellular, and environmental factors over time. Such dynamics are difficult to represent using static risk models, particularly in biologically heterogeneous conditions such as pediatric acute lymphoblastic leukemia (ALL). Here, we present a large concept model (LCM) as a mechanistic, hypothesis-generating framework for simulating longitudinal disease trajectories using pediatric ALL relapse dynamics as a proof-of-concept exemplar.\n                    <jats:bold>Methods:<\/jats:bold>\n                    We developed a causal longitudinal modeling framework implemented within the aiHumanoid v11.0 platform to characterize post-remission relapse dynamics. Seven clinically relevant ETV6::RUNX1-based genotypic profiles were simulated from remission baseline (T0) through 2 post-remission intervals (T1 = 3 months; T2 = 6 months). Longitudinal remission-to-relapse changes were evaluated across genotype- and age-defined virtual cohorts using descriptive nonparametric effect-size-oriented measures. Relapse dynamics were summarized using 2 composite system-level metrics: the relapse risk score and relapse pressure index.\n                    <jats:bold>Results:<\/jats:bold>\n                    The model generated distinct genotype- and age-associated trajectory patterns across relapse-relevant biological domains and produced composite measures reflecting modeled relapse pressure within the simulation environment. Greater relapse-associated biological divergence was observed in selected genotype\u2013age strata, particularly in domains related to clonal evolution, treatment resistance, and minimal residual disease.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    This ALL-focused proof of concept demonstrates the architectural and analytic potential of mechanistic trajectory simulation for hypothesis generation, longitudinal systems modeling, and future integration with real-world longitudinal datasets.\n                  <\/jats:p>","DOI":"10.34133\/csbj.0154","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T17:18:56Z","timestamp":1781025536000},"update-policy":"https:\/\/doi.org\/10.34133\/aaas_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["A Large Concept Model for Mechanistic Simulation of Disease Trajectories: A Hypothesis-Generating Exemplar for Pediatric Acute Lymphoblastic Leukemia"],"prefix":"10.34133","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9297-4405","authenticated-orcid":false,"given":"Wayne R.","family":"Danter","sequence":"first","affiliation":[{"name":"HumanQAI Inc. (formerly 123Genetix Inc.), London","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM194806032382301"},{"issue":"5","key":"e_1_3_5_3_2","first-page":"846","article-title":"Total therapy of acute lymphocytic leukemia","volume":"48","author":"Pinkel D","year":"1971","unstructured":"Pinkel D, Simone JV, Hustu HO, Aur RJ. Total therapy of acute lymphocytic leukemia. Pediatrics. 1971;48(5):846\u2013857.","journal-title":"Pediatrics"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62187-4"},{"issue":"27","key":"e_1_3_5_5_2","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: Progress through collaboration","volume":"33","author":"Pui CH","year":"2015","unstructured":"Pui CH, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, Vora A, Baruchel A, Silverman LB, Schmiegelow K, et al. Childhood acute lymphoblastic leukemia: Progress through collaboration. J Clin Oncol. 2015;33(27):2938\u20132948.","journal-title":"J Clin Oncol"},{"issue":"1","key":"e_1_3_5_6_2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3324\/haematol.2015.131680","article-title":"Relapsed childhood acute lymphoblastic leukaemia in the Nordic countries: Risk factors, treatment and outcome","volume":"101","author":"Oskarsson T","year":"2016","unstructured":"Oskarsson T, S\u00f6derh\u00e4ll S, Arvidson J, Forestier E, Montgomery S, Bottai M, Lausen B, Carlsen N, Hellebostad M, L\u00e4hteenm\u00e4ki P, et al. Relapsed childhood acute lymphoblastic leukaemia in the Nordic countries: Risk factors, treatment and outcome. Haematologica. 2016;101(1):68\u201376.","journal-title":"Haematologica"},{"issue":"1","key":"e_1_3_5_7_2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1586\/17474086.2015.978281","article-title":"Risk factors for relapse in childhood acute lymphoblastic leukemia","volume":"8","author":"Ceppi F","year":"2015","unstructured":"Ceppi F, Cazzaniga G, Colombini A, Biondi A, Conter V. Risk factors for relapse in childhood acute lymphoblastic leukemia. Expert Rev Hematol. 2015;8(1):57\u201370.","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"e_1_3_5_8_2","first-page":"574","article-title":"Treatment and outcome of relapsed childhood T-cell acute lymphoblastic leukaemia: Results from the UKALLR3 trial","volume":"105","author":"Hughes A","year":"2020","unstructured":"Hughes A, Wade R, Richards S, Hancock J, Vora A, Mitchell C. Treatment and outcome of relapsed childhood T-cell acute lymphoblastic leukaemia: Results from the UKALLR3 trial. Haematologica. 2020;105(3):574\u2013582.","journal-title":"Haematologica"},{"issue":"2","key":"e_1_3_5_9_2","first-page":"456","article-title":"Determinants of survival after first relapse of acute lymphoblastic leukemia","volume":"38","author":"Rheingold SR","year":"2024","unstructured":"Rheingold SR, Salzer WL, Devidas M, Borowitz MJ, Carroll AJ, Gastier-Foster JM, et al. Determinants of survival after first relapse of acute lymphoblastic leukemia. Leukemia. 2024;38(2):456\u2013468.","journal-title":"Leukemia"},{"issue":"6","key":"e_1_3_5_10_2","first-page":"1231","article-title":"Enhanced risk stratification for children and young adults with ALL: The PI-UKALL score","volume":"38","author":"Del Rocco NJ","year":"2024","unstructured":"Del Rocco NJ, Annesley CE, Alexander TB, Bartram J, Attarbaschi A, Moorman AV. Enhanced risk stratification for children and young adults with ALL: The PI-UKALL score. Leukemia. 2024;38(6):1231\u20131242.","journal-title":"Leukemia"},{"key":"e_1_3_5_11_2","first-page":"154","article-title":"Risk factors and outcomes in children with high-risk B-cell acute lymphoblastic leukemia","volume":"499","author":"Eckert C","year":"2021","unstructured":"Eckert C, von Stackelberg A, Seeger K, Groeneveld-Krentz S, Cario G, Schrauder A. Risk factors and outcomes in children with high-risk B-cell acute lymphoblastic leukemia. Cancer Lett. 2021;499:154\u2013164.","journal-title":"Cancer Lett"},{"issue":"3","key":"e_1_3_5_12_2","first-page":"221","article-title":"Poverty and relapse risk in children with acute lymphoblastic leukaemia","volume":"142","author":"Slayton WB","year":"2023","unstructured":"Slayton WB, Devidas M, Hunger SP, Heerema NA, Carroll AJ, Winick NJ. Poverty and relapse risk in children with acute lymphoblastic leukaemia. Blood. 2023;142(3):221\u2013232.","journal-title":"Blood"},{"key":"e_1_3_5_13_2","volume-title":"PDQ childhood acute lymphoblastic leukemia treatment","author":"NCI PDQ Pediatric Treatment Editorial Board","year":"2025","unstructured":"NCI PDQ Pediatric Treatment Editorial Board. PDQ childhood acute lymphoblastic leukemia treatment. Bethesda (MD): National Cancer Institute; 2025."},{"key":"e_1_3_5_14_2","doi-asserted-by":"crossref","unstructured":"Danter WR. Investigating genetic and familial risks in childhood ALL: A longitudinal virtual study using aiHumanoid simulations of TEL-AML1 gene fusion. medRxiv. 2024. https:\/\/doi.org\/10.1101\/2024.06.19.24309162","DOI":"10.1101\/2024.06.19.24309162"},{"issue":"3","key":"e_1_3_5_15_2","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1037\/0033-2909.114.3.494","article-title":"Dominance statistics: Ordinal analyses to answer ordinal questions","volume":"114","author":"Cliff N","year":"1993","unstructured":"Cliff N. Dominance statistics: Ordinal analyses to answer ordinal questions. Psychol Bull. 1993;114(3):494\u2013509.","journal-title":"Psychol Bull"},{"issue":"2","key":"e_1_3_5_16_2","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1214\/aoms\/1177704172","article-title":"Estimates of location based on rank tests","volume":"34","author":"Hodges JL","year":"1963","unstructured":"Hodges JL, Lehmann EL. Estimates of location based on rank tests. Ann Math Stat. 1963;34(2):598\u2013611.","journal-title":"Ann Math Stat"},{"key":"e_1_3_5_17_2","unstructured":"Barrault L Duquenne P-A Elbayad M Kozhevnikov A Alastruey B Andrews P Coria M Couairon G Costa-juss\u00e0 MR Dale D Elsahar H Heffernan K Janeiro JM Tran T Ropers C S\u00e1nchez E San Roman R Mourachko A Saleem S Schwenk H. Large concept models: Language modeling in a sentence representation space. arXiv. 2024. https:\/\/doi.org\/10.48550\/arXiv.2412.08821"},{"key":"e_1_3_5_18_2","doi-asserted-by":"crossref","unstructured":"Danter WR. aiAtlas: High-fidelity cell simulations of genetic perturbations in rare diseases and cancers. bioRxiv. 2025. https:\/\/doi.org\/10.1101\/2025.10.20.683396","DOI":"10.1101\/2025.10.20.683396"},{"key":"e_1_3_5_19_2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s44313-025-00085-3","article-title":"Improved survival in pediatric acute lymphoblastic leukemia through therapy intensification based on minimal residual disease and protocol-driven early response risk classification","volume":"60","author":"Kim H","year":"2025","unstructured":"Kim H, Yoon SH, Kang S, Koh KN, Im HJ, Chu D, Kim MY, Cho YU, Hwang SH, Jang S. Improved survival in pediatric acute lymphoblastic leukemia through therapy intensification based on minimal residual disease and protocol-driven early response risk classification. Blood Res. 2025;60:40.","journal-title":"Blood Res"},{"key":"e_1_3_5_20_2","doi-asserted-by":"crossref","first-page":"1570041","DOI":"10.3389\/fmed.2025.1570041","article-title":"The emerging role of next-generation sequencing in minimal residual disease assessment in acute lymphoblastic leukemia: A systematic review","volume":"12","author":"\u0218tefan AI","year":"2025","unstructured":"\u0218tefan AI, Radu LE, Jardan D, Coli\u021b\u0103 A. The emerging role of next-generation sequencing in minimal residual disease assessment in acute lymphoblastic leukemia: A systematic review. Front Med. 2025;12:1570041.","journal-title":"Front Med"},{"issue":"1","key":"e_1_3_5_21_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12288-023-01641-6","article-title":"Minimal residual disease in the management of B-cell acute lymphoblastic leukemia: A systematic review of studies from Indian settings","volume":"40","author":"Menon H","year":"2024","unstructured":"Menon H, Singh PK, Bagal B, Dolai T, Jain A, Chaudhri A. Minimal residual disease in the management of B-cell acute lymphoblastic leukemia: A systematic review of studies from Indian settings. Indian J Hematol Blood Transfus. 2024;40(1):1\u201311.","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"1","key":"e_1_3_5_22_2","doi-asserted-by":"crossref","DOI":"10.1038\/s41746-024-01073-0","article-title":"Digital twins for health: A scoping review","volume":"7","author":"Katsoulakis E","year":"2024","unstructured":"Katsoulakis E, Wang Q, Wu H, Shahriyari L, Fletcher R, Liu J, Achenie L, Liu H, Jackson P, Xiao Y, et al. Digital twins for health: A scoping review. NPJ Digit Med. 2024;7(1): Article 77.","journal-title":"NPJ Digit Med"},{"issue":"2","key":"e_1_3_5_23_2","first-page":"e123","article-title":"Medical digital twins: Enabling precision medicine and personalized healthcare delivery","volume":"7","author":"Sad\u00e9e C","year":"2025","unstructured":"Sad\u00e9e C, Brochard J, van der Garde M, Chouvarda I, Garcia-Remesal M, Roca J. Medical digital twins: Enabling precision medicine and personalized healthcare delivery. Lancet Digit Health. 2025;7(2):e123\u2013e134.","journal-title":"Lancet Digit Health"},{"issue":"10","key":"e_1_3_5_24_2","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.3390\/jcm14103574","article-title":"Exploring the potential of digital twins in cancer treatment","volume":"14","author":"Giansanti D","year":"2025","unstructured":"Giansanti D, Morelli S. Exploring the potential of digital twins in cancer treatment. J Clin Med. 2025;14(10):3574.","journal-title":"J Clin Med"},{"key":"e_1_3_5_25_2","first-page":"119","article-title":"Advancing precision oncology with digital and virtual twins","volume":"15","author":"Zhuang Y","year":"2025","unstructured":"Zhuang Y, Zhao J, Li H, Zhang T, Sun H. Advancing precision oncology with digital and virtual twins. Front Oncol. 2025;15:119\u2013132.","journal-title":"Front Oncol"},{"key":"e_1_3_5_26_2","doi-asserted-by":"crossref","first-page":"1007784","DOI":"10.3389\/fdgth.2022.1007784","article-title":"Exploring approaches for predictive cancer patient digital twins: Opportunities for collaboration and innovation","volume":"4","author":"Stahlberg EA","year":"2022","unstructured":"Stahlberg EA, Abdel-Rahman M, Aguilar B, Asadpoure A, Beckman RA, Borkon LL, Bryan JN, Cebulla CM, Chang YH, Chatterjee A, et al. Exploring approaches for predictive cancer patient digital twins: Opportunities for collaboration and innovation. Front Digit Health. 2022;4:1007784.","journal-title":"Front Digit Health"},{"key":"e_1_3_5_27_2","doi-asserted-by":"crossref","DOI":"10.2196\/72411","article-title":"Digital twins for personalized medicine require epidemiological data and mathematical modeling: Viewpoint","volume":"27","author":"Vall\u00e9e A","year":"2025","unstructured":"Vall\u00e9e A. Digital twins for personalized medicine require epidemiological data and mathematical modeling: Viewpoint. J Med Internet Res. 2025;27: Article e72411.","journal-title":"J Med Internet Res"}],"container-title":["Computational and Structural Biotechnology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.34133\/csbj.0154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T08:00:45Z","timestamp":1782806445000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.34133\/csbj.0154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3,1]]}},"alternative-id":["10.34133\/csbj.0154"],"URL":"https:\/\/doi.org\/10.34133\/csbj.0154","relation":{},"ISSN":["2001-0370"],"issn-type":[{"value":"2001-0370","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]},"assertion":[{"value":"2026-03-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"0154"}}